{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:07:10Z","timestamp":1771538830976,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20190173"],"award-info":[{"award-number":["BK20190173"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52033006"],"award-info":[{"award-number":["52033006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000157"],"award-info":[{"award-number":["82000157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bioactmat.2022.08.032","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:26:03Z","timestamp":1663673163000},"page":"499-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia"],"prefix":"10.1016","volume":"21","author":[{"given":"Yifeng","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingnan","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songsong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cenzhu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioactmat.2022.08.032_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41375-021-01164-x","article-title":"Two decades of targeted therapies in acute myeloid leukemia","volume":"35","author":"Cucchi","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib3","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1073\/pnas.1902375116","article-title":"Heterogeneity in refractory acute myeloid leukemia","volume":"116","author":"Horibata","year":"2019","journal-title":"P. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101896","article-title":"Molecular targeted therapy of glioblastoma","volume":"80","author":"Le Rhun","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib7","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-12-195867","article-title":"Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells","volume":"114","author":"Renner","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib9","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","article-title":"A phase Ib study of Onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"26","author":"Zeidan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib10","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1097\/HS9.0000000000000617","article-title":"Adjunctive volasertib in patients with acute myeloid leukemia not eligible for standard induction therapy: a randomized, phase 3 trial","volume":"5","author":"D\u00f6hner","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.leukres.2014.06.007","article-title":"Orphan drug designation for pracinostat, volasertib and alvocidib in AML","volume":"38","author":"Bose","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood.V120.21.411.411","volume":"120","author":"Maertens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib13","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/cas.12814","article-title":"Phase I trial of volasertib, a polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia","volume":"106","author":"Kobayashi","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2020.10.003","article-title":"Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation","volume":"329","author":"Gu","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"van der Meel","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jconrel.2021.08.001","article-title":"Polymeric nanomedicines targeting hematological malignancies","volume":"337","author":"Gu","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/mt.2013.32","article-title":"Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors","volume":"21","author":"Senzer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib18","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1158\/1078-0432.CCR-12-3191","article-title":"Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia","volume":"19","author":"Huang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.actbio.2021.02.007","article-title":"\u03b13 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer","volume":"124","author":"Wang","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.actbio.2020.06.020","article-title":"GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma","volume":"113","author":"Zhou","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007787","article-title":"Daratumumab immunopolymersome-enabled safe and CD38-targeted chemotherapy and depletion of multiple myeloma","volume":"33","author":"Yu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib22","doi-asserted-by":"crossref","first-page":"99752","DOI":"10.1039\/C6RA22896H","article-title":"Synthesis of well-defined core-shell nanoparticles based on bifunctional poly(2-oxazoline) macromonomer surfactants and a microemulsion polymerization process","volume":"6","author":"Kampmann","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jconrel.2021.06.032","article-title":"Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma","volume":"336","author":"Xia","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201904742","article-title":"CD44-specific A6 short peptide boosts targetability and anticancer efficacy of polymersomal epirubicin to orthotopic human multiple myeloma","volume":"31","author":"Gu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib25","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/mt.2016.135","article-title":"Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study","volume":"24","author":"Pirollo","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/mt.2016.118","article-title":"A phase l study of a tumor-targeted systemic nanodelivery system, SGT-94, in genitourinary cancers","volume":"24","author":"Siefker-Radtke","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2141.2001.03065.x","article-title":"Molecular analysis of transferrin receptor mRNA expression in acute myeloid leukaemia","volume":"115","author":"Kollia","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1073\/pnas.0914140107","article-title":"Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles","volume":"107","author":"Choi","year":"2010","journal-title":"P. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.actbio.2019.05.034","article-title":"Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo","volume":"92","author":"Wei","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jclinpath-2016-203656","article-title":"Molecular interactions of polo-like kinase 1 in human cancers","volume":"69","author":"Weng Ng","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib31","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.celrep.2017.05.031","article-title":"PLK1 activation in late G2 sets up commitment to mitosis","volume":"19","author":"Gheghiani","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/JEP.S259287","article-title":"Up-and-coming experimental drug options for metastatic colorectal cancer","volume":"12","author":"Cimino","year":"2020","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib33","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1038\/s41467-020-17697-1","article-title":"PLK1 inhibition exhibits strong anti-tumoral activity in CCND1 -driven breast cancer metastases with acquired palbociclib resistance","volume":"11","author":"Montaudon","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1535-7163.MCT-16-0361","article-title":"Targeting Plk1 to enhance efficacy of olaparib in castration-resistant prostate cancer","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41417-019-0094-x","article-title":"PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3","volume":"27","author":"Gao","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib36","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","article-title":"A phase Ib study of Onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"26","author":"Zeidan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41467-017-02283-9","article-title":"Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer","volume":"9","author":"Gibori","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2014.222","article-title":"Discovery and development of the polo-like kinase inhibitor volasertib in cancer therapy","volume":"29","author":"Gjertsen","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib39","doi-asserted-by":"crossref","first-page":"14066","DOI":"10.1074\/jbc.M114.558155","article-title":"Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle","volume":"289","author":"Choi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","article-title":"PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells","volume":"4","author":"Bleau","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib41","doi-asserted-by":"crossref","first-page":"78452","DOI":"10.18632\/oncotarget.19632","article-title":"Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia","volume":"8","author":"Adachi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201904742","article-title":"CD44-specific A6 short peptide boosts targetability and anticancer efficacy of polymersomal epirubicin to orthotopic human multiple myeloma","volume":"31","author":"Gu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib43","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib44","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jconrel.2020.10.005","article-title":"A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia","volume":"329","author":"Gu","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib46","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1021\/mp4001266","article-title":"Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease","volume":"10","author":"Shi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib47","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41591-018-0082-y","article-title":"DPP8\/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia","volume":"24","author":"Johnson","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41467-017-02618-6","article-title":"Peptidomimetic blockade of MYB in acute myeloid leukemia","volume":"9","author":"Ramaswamy","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib49","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/cas.12814","article-title":"Phase I trial of volasertib, a polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia","volume":"106","author":"Kobayashi","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioactmat.2022.08.032_bib50","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/leu.2017.259","article-title":"Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2022.08.032_bib51","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1073\/pnas.1422749112","article-title":"Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia","volume":"112","author":"\u00c5gerstam","year":"2015","journal-title":"P. Natl. Acad. Sci. USA"}],"updated-by":[{"DOI":"10.1016\/j.bioactmat.2023.08.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000}}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X22003760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X22003760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T21:30:40Z","timestamp":1673213440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X22003760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"alternative-id":["S2452199X22003760"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2022.08.032","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bioactmat.2023.08.011","asserted-by":"object"}]},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2022.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}